Cidara Therapeutics, Inc. (NASDAQ:CDTX) – Investment analysts at Leerink Swann upped their FY2017 earnings estimates for Cidara Therapeutics in a research report issued on Thursday. Leerink Swann analyst P. Matteis now expects that the biotechnology company will post earnings per share of ($3.14) for the year, up from their previous forecast of ($3.80). Leerink Swann also issued estimates for Cidara Therapeutics’ Q4 2017 earnings at ($0.63) EPS, Q1 2018 earnings at ($0.66) EPS, Q2 2018 earnings at ($0.50) EPS, Q4 2018 earnings at ($0.87) EPS, FY2018 earnings at ($2.75) EPS and FY2019 earnings at ($3.17) EPS.
A number of other research firms also recently weighed in on CDTX. Cantor Fitzgerald set a $15.00 price target on Cidara Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 10th. WBB Securities upgraded Cidara Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Zacks Investment Research cut Cidara Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. ValuEngine cut Cidara Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Finally, HC Wainwright lifted their price objective on Cidara Therapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $13.39.
TRADEMARK VIOLATION WARNING: This piece was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://ledgergazette.com/2017/11/13/cidara-therapeutics-inc-cdtx-expected-to-earn-fy2017-earnings-of-3-14-per-share.html.
Cidara Therapeutics (NASDAQ:CDTX) opened at $7.80 on Monday. Cidara Therapeutics has a twelve month low of $5.60 and a twelve month high of $11.85. The company has a current ratio of 7.69, a quick ratio of 7.69 and a debt-to-equity ratio of 0.16.
Cidara Therapeutics (NASDAQ:CDTX) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.94) by $0.21.
In related news, CEO Jeffrey Stein bought 7,350 shares of Cidara Therapeutics stock in a transaction dated Tuesday, September 12th. The shares were acquired at an average cost of $6.79 per share, with a total value of $49,906.50. Following the completion of the transaction, the chief executive officer now owns 51,851 shares in the company, valued at approximately $352,068.29. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 18.90% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in Cidara Therapeutics by 77.4% in the third quarter. JPMorgan Chase & Co. now owns 41,266 shares of the biotechnology company’s stock valued at $328,000 after acquiring an additional 18,001 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Cidara Therapeutics by 37.2% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 23,985 shares of the biotechnology company’s stock worth $194,000 after purchasing an additional 6,500 shares during the last quarter. Broadfin Capital LLC raised its holdings in shares of Cidara Therapeutics by 45.0% during the second quarter. Broadfin Capital LLC now owns 816,275 shares of the biotechnology company’s stock worth $6,122,000 after purchasing an additional 253,400 shares during the last quarter. Susquehanna International Group LLP purchased a new position in shares of Cidara Therapeutics during the second quarter worth $350,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Cidara Therapeutics during the second quarter worth $650,000. Hedge funds and other institutional investors own 66.11% of the company’s stock.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.